||Medtronic IBERICA (ES), IDS SCHEER CR, S.R.O (CH), KUOPION YLIOPISTO (FI), MEGA ELECTRONICS LTD (FI), MICRODATA (GR), University of Patras (GR), MEDMARK LTD (SL), FERRARI (IT), UNIVERSITAET AUGSBURG (D), D.D. SYNERGY (GR), ORT FRANCE (FR), UNIVERZITA KARLOVA V PRAZE (CR), UNIVERSITA' DEGLI STUDI DI PARMA (IT), HOSPITAL CLINICO SAN CARLOS (ES), SWORD TECHNOLOGIES SA (LU), R&S INFO S.R.L. (IT), WORLD MATCH LIMITED (MA), UNIVERSIDAD POLITECNICA DE MADRID (ES), AZIENDA UNITA SANITARIA LOCALE DI MODENA (IT), UNIVERSIDAD POLITECNICA DE VALENCIA (ES), ICCS (GR), S.A.T.E. (IT)
||The aim of METABO is to set up a comprehensive platform, running both in clinical settings and in every-day life environments, for continuous and multi-parametric monitoring of the metabolic status in patients with, or at risk of, diabetes and associated metabolic disorders. The type of parameters that will be monitored, in addition to “traditional” clinical and biomedical parameters, will also include subcutaneous glucose concentration, dietary habits, physical activity and energy expenditure, effects of ongoing treatments, and autonomic reactions.